KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Cash from Financing Activities: 2019-2024

Historic Cash from Financing Activities for AbCellera Biologics (ABCL) over the last 6 years, with Dec 2024 value amounting to $12.8 million.

  • AbCellera Biologics' Cash from Financing Activities rose 134.40% to $7.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.1 million, marking a year-over-year increase of 13.86%. This contributed to the annual value of $12.8 million for FY2024, which is 23.30% up from last year.
  • As of FY2024, AbCellera Biologics' Cash from Financing Activities stood at $12.8 million, which was up 23.30% from $10.4 million recorded in FY2023.
  • In the past 5 years, AbCellera Biologics' Cash from Financing Activities ranged from a high of $683.7 million in FY2020 and a low of -$3.9 million during FY2021.
  • For the 3-year period, AbCellera Biologics' Cash from Financing Activities averaged around $7.2 million, with its median value being $10.4 million (2023).
  • Per our database at Business Quant, AbCellera Biologics' Cash from Financing Activities skyrocketed by 350,491.28% in 2020 and then slumped by 100.57% in 2021.
  • AbCellera Biologics' Cash from Financing Activities (Yearly) stood at $683.7 million in 2020, then tumbled by 100.57% to -$3.9 million in 2021, then skyrocketed by 58.11% to -$1.6 million in 2022, then surged by 736.12% to $10.4 million in 2023, then increased by 23.30% to $12.8 million in 2024.